Kaiser on panel for American Conference Institute’s 4th Annual Legal, Regulatory and Compliance Forum on Dietary Supplements

June 27, 2016 | Compliance Investigations & White Collar | Health Services

Geoffrey Kaiser will be a co-presenter at the American Conference Institute’s (ACI) 4th Annual Legal, Regulatory and Compliance Forum on Dietary Supplements, which takes place on June 27-28, 2016 at The Andaz Wall Street, New York City.

This forum includes preeminent counsel, regulatory and compliance executives, and officials from leading trade associations representing the dietary supplement industry as they share their insights and help you:

  • Prepare for the new priorities set forth by the newly established Office of Dietary Supplement Programs (ODSP)
  • Comprehend the significance of USP Labs vis-à-vis individual criminal indictments and the application of the Yates memo
  • Assess the FDA’s enforcement agenda for the dietary supplement industry through warning letter analysis
  • Analyze current FTC and NAD hot spots in the aftermath of FTC v. Bayer and Lumosity
  • Devise strategies to minimize class action exposure and mitigate liability
  • Find solutions to the challenges presented by the next wave of FSMA regulation implementation
  • Identify impediments and risks to successful M&A and IPO positioning
  • Explore industry self-policing initiatives to promote transparency and integrity
  • Anticipate the requirements of the FDA’s NDI Guidance, revised Nutrition and Supplement Facts Label, and definition of natural
  • Understand how specific changes to California’s Prop 65 law will affect the industry
  • Evaluate the applicability of the Vermont GMO labeling law to dietary supplement products

Jeff’s program is entitled, “Understanding New Government Enforcement Priorities in the Aftermath of USP Labs and What it Means for the Dietary Supplement Industry.”

Program descriptive:

This past November, the Justice Department announced the filing of multiple criminal and civil cases against several dietary supplement manufacturers for falsified labeling and product misrepresentation. In addition to a criminal indictment of the company in one of these cases, i.e., USP Labs, company officers and directors were also individually indicted, thus dramatically

changing the enforcement landscape in the dietary supplements arena.

This panel will examine the repercussions of this new enforcement wave and what it means for the industry. Points of discussion will include:

  • Analysis of USP Labs and its implications for:
    • corporations vs. individuals
    • manufacturers vs. retailers
  • Comprehending the significance of individual criminal indictments and the Yates Memo to the supplement industry
  • Exploring the implications of this case for civil actions
  • Predicting future enforcement activity concerning importation, cGMPs, FCPA compliance, etc.
  • Analysis of other Federal Partners “clean sweep” actions and their significance
  • Examining joint FDA and DOJ enforcement actions against bad actors

Click here to register and for more information.

Share this article:

Related News

Get legal updates and news delivered to your inbox